Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ages 1-17 yr. followed at participating centers~* diagnosed with primary ITP~* present with a PC \< 20 x 10\^9/L~* patient and attending physician have decided on treatment of ITP~Exclusion Criteria:~* initial presentation with ITP~* splenectomy~* life-threatening hemorrhage e.g. proven or suspected intracranial hemorrhage (ICH), major gastrointestinal hemorrhage with cardiorespiratory decompensation~* organ-threatening hemorrhage e.g. hemorrhage into the eye~* contraindication to IVIG ( renal disease with creatinine \> x 2 upper list of normal )~* contraindication of IV methylprednisolone ( diabetes mellitus, hypertension, peptic ulceration )~* prior failure to attain a PC level over 50 X 109 within 2 weeks of treatment with IVIG of 0.8 to 1 g/kg or IV methyl-prednisolone (max 1 gram ) within 6 months prior to study entry~* co-existing situations that could affect platelet response to therapy e.g. sepsis, fever \> 38.5°C ( orally or equivalent), splenomegaly (spleen tip \> 2 cm below costal margin), Disseminated Intravascular Coagulation (DIC) - defined by a fibrinogen level \< 1.0 g/dL and elevated D-dimer levels, surgery~* pregnancy (a mandatory urine pregnancy test will be obtained on all post-pubescent female patients). Such patients can only be eligible once the urine pregnancy test results are confirmed to be negative.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Placebo and IVIG (Type: ACTIVE_COMPARATOR): The trial site is blinded to the randomization process. Patients are assigned an arm by a research pharmacist. Patients on this arm receive an infusion of placebo (0.9% NaCl) over one hour. Immediately following this dosing, 1 g/kg IVIG (Gammunex ©) is infused over 2 - 3 hours. Following this treatment, complete blood counts are drawn at:~* completion of IVIG infusion,~* 8 hours following the start of the placebo/solumedrol infusion~* 24 hours following the start of the placebo/solumedrol infusion~* 72 hours following the start of the placebo/solumedrol infusion~* 7 days post infusion~* 21 days post infusion
- Methylprednisolone and IVIG (Type: EXPERIMENTAL): The trial site is blinded to the randomization process. Patients are assigned an arm by a research pharmacist.Patients on this arm receive IV Methylprednisolone 30 mg/kg (1 gram maximum) infused over one hour. Immediately following this dosing, 1 g/kg IVIG Gammunex © is infused over 2 - 3 hours. Following this treatment, complete blood counts are drawn at:~* completion of IVIG infusion,~* 8 hours following the start of the placebo/solumedrol infusion~* 24 hours following the start of the placebo/solumedrol infusion~* 72 hours following the start of the placebo/solumedrol infusion~* 7 days post infusion~* 21 days post infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).